HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
Meng Hsuan KuoChih-Wei TsengPing-Hung KoSz-Tsan WangMing-Chi LuChien-Hsueh TungKuo-Chih TsengKuang-Yung HuangChi-Hui LeeNing-Sheng LaiPublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
HBsAg-/HBcAb+ RA patients are susceptible to HBV reactivation during b/tsDMARD therapy. Those with negative baseline anti-HBs and those on certain b/tsDMARDs, such as rituximab, abatacept and adalimumab, have high reactivation risks. Risk stratification and management should be based on the patient's baseline anti-HBs titre and type of therapy.
Keyphrases
- rheumatoid arthritis
- hepatitis b virus
- disease activity
- end stage renal disease
- ankylosing spondylitis
- ejection fraction
- rheumatoid arthritis patients
- interstitial lung disease
- liver failure
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- case report
- cancer therapy
- systemic lupus erythematosus
- human health
- climate change
- bone marrow
- ulcerative colitis